Clinical Trial

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms

Study acronym: Drugs-SNPs
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Explore the relationship between drug target topoisomerase II gene single nucleotide polymorphisms and Etoposide (VP-16) therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and Etoposide (VP-16) side-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.
Protocol Amendment History 101 amendments
This ClinicalTrials.gov record has been amended 101 times since 2010-02-04; most recent amendment 2025-07-23.
Status change: Not Yet Recruiting → Active, Not Recruiting 2011-07-19
Trial Details
NCT Number NCT01064466
Lead Sponsor Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Collaborators: UnitedHealthcare
Conditions Small Cell Lung Cancer
Enrollment 600 participants
Start Date 2025-07-16
Primary Completion 2026-11-18 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2025-07-24